Catalog No.
Product Name
Application
Product Information
Citations
-
DPP4 Inhibitor
Evogliptin tartrate is an orally active DPP4 inhibitor that exhibits significant and sustained hypoglycemic effects in murine models. It not only lowers blood glucose levels but also attenuates the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. This compound is suitable for research applications related to type 2 diabetes, osteoporosis, renal impairment, and chronic liver inflammation. -
DHODH Inhibitor
DHODH-IN-8 is a selective inhibitor of dihydroorotate dehydrogenase (DHODH) in both human and Plasmodium falciparum, exhibiting IC50 values of 0.13 μM and 47.4 μM, respectively. Additionally, it demonstrates Kis of 0.016 μM for human DHODH and 5.6 μM for the parasite's enzyme. This compound shows significant antimalarial activity, making it a valuable tool for research into malaria treatment and the inhibition of the pyrimidine biosynthesis pathway. -
DHODH Inhibitor
DHODH-IN-20 is a potent inhibitor of dihydroorotate dehydrogenase (DHODH), an iron-containing flavin-dependent enzyme located in the inner mitochondrial membrane of human cells. By inhibiting DHODH, this compound exhibits significant anti-tumor activity, making it a valuable tool in the study of cancer biology. DHODH-IN-20 is particularly relevant for research focused on acute myelogenous leukemia, offering insights into potential therapeutic strategies. -
HsDHODH Inhibitor
DHODH-IN-3 is a selective inhibitor of Human Dihydroorotate Dehydrogenase (HsDHODH), demonstrating a potent inhibitory effect with an IC50 value of 261 nM. By targeting the ubiquinone binding sites within the enzyme, DHODH-IN-3 exhibits a competitive inhibition profile, characterized by a Kiapp of 32 nM. This compound shows promise for therapeutic applications in malaria research, potentially contributing to the development of novel treatments. -
DHODH Inhibitor
DHODH-IN-12 is a derivative of Leflunomide that functions as a dihydroorotate dehydrogenase (DHODH) inhibitor. This compound displays weak inhibitory activity against DHODH, making it a valuable tool for studying the modulation of pyrimidine metabolism. Its applications include investigations into immunological diseases and the development of therapeutics targeting nucleotide synthesis pathways. The pKa of 5.07 further informs its solubility and stability characteristics in biological systems. -
hDHODH Inhibitor
hDHODH-IN-2 is a selective inhibitor of human dihydroorotate dehydrogenase (hDHODH), functioning as an analogue of Leflunomide's active metabolite. This compound exhibits anti-inflammatory properties, making it relevant for research into autoimmune diseases and other inflammatory conditions. Its mechanism of action targets pyrimidine synthesis, effectively reducing the production of lymphocytes involved in inflammatory responses. -
DHODH Inhibitor
DHODH-IN-13 is a potent inhibitor of dihydroorotate dehydrogenase (DHODH), displaying an IC50 of 4.3 μM for rat liver DHODH. This hydroxyfurazan analog of A771726 demonstrates significant biological activity in modulating pyrimidine metabolism. DHODH-IN-13 is primarily utilized in research related to rheumatoid arthritis and other autoimmune conditions, making it a valuable tool for exploring therapeutic strategies in these areas. -
hDHODH Inhibitor
hDHODH-IN-14 is a potent inhibitor of human dihydroorotate dehydrogenase (hDHODH), exhibiting an IC50 value of 0.469 μM. This compound is utilized primarily in research focused on modulating the de novo pyrimidine biosynthesis pathway. Its inhibitory effects make hDHODH-IN-14 a valuable reagent for studying metabolic processes and potential therapeutic strategies in various diseases, including autoimmune disorders and cancer. -
DHODH Inhibitor
DHODH-IN-19 is a potent inhibitor of dihydroorotate dehydrogenase (DHODH), an essential enzyme located in the inner membrane of human mitochondria that is critical for pyrimidine biosynthesis. This compound demonstrates significant anticancer activity by inhibiting tumor growth, making it a valuable tool for research in cancer and inflammatory diseases. Its mechanism of action offers potential insights into the metabolic pathways involved in these conditions. -
DHODH Inhibitor
hDHODH-IN-7 is a selective inhibitor of human dihydroorotate dehydrogenase (DHODH). It exhibits antiviral activity with a reported pMIC50 of 7.4, indicating its potential efficacy in reducing viral replication. This compound is suitable for research applications involving the study of viral infections and the regulation of pyrimidine biosynthesis. -
DHODH Inhibitor
DHODH-IN-15 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor, exhibiting an IC50 of 11 μM in rat liver DHODH assays. This hydroxyfurazan analog of A771726 demonstrates significant biological activity, making it a valuable tool for investigating the role of DHODH in various metabolic pathways. Its application extends to research on rheumatoid arthritis, contributing to the understanding of therapeutic strategies for inflammatory diseases. -
DHODH Inhibitor
DHODH-IN-25 is a potent inhibitor of dihydroorotate dehydrogenase (DHODH) with an IC50 value of 5.4 nM for human DHODH. This compound demonstrates significant biological activity and is particularly relevant for research applications involving acute myeloid leukemia (AML). DHODH-IN-25 provides valuable insights into the therapeutic potential of targeting pyrimidine biosynthesis in cancer treatment. -
DHODH Inhibitor
DHODH-IN-4 is a dihydroorotate dehydrogenase (DHODH) inhibitor targeting both human and Plasmodium falciparum DHODH. With IC50 values of 4 μM for PfDHODH and 0.18 μM for HsDHODH, this compound demonstrates significant potential as an antimalarial agent. It is suitable for research applications focused on understanding malaria pathology and developing effective treatments against Plasmodium infections. -
DHODH Inhibitor
DHODH-IN-24 is a potent inhibitor of human dihydroorotate dehydrogenase (DHODH) with an IC50 value of 91 nM. This compound effectively impairs the proliferation of rapidly dividing cells by hindering pyrimidine synthesis. DHODH-IN-24 is an important tool for investigating the role of DHODH in various biological processes and may have applications in the research of autoimmune diseases and cancer therapy. -
DHODH Inhibitor
P1788 is a selective inhibitor of dihydroorotate dehydrogenase (DHODH), a key enzyme in the de novo pyrimidine synthesis pathway. By inhibiting DHODH, P1788 induces DNA damage and has demonstrated potential in various cancer research applications. Its effects on pyrimidine metabolism make it a valuable tool for studying cellular proliferation and apoptosis. -
RORγ/DHODH Inhibitor
RORγ/DHODH-IN-1 is a dual inhibitor targeting RORγ and dihydroorotate dehydrogenase (DHODH) with IC50 values of 9.7 nM and 100 nM, respectively. This compound effectively inhibits the replication of SARS-CoV-2, human cytomegalovirus (HCMV), and adenovirus type 5 (HAdV5), making it a valuable tool in viral research. Its dual mechanism of action allows for potential applications in understanding viral-pathogen interactions and developing therapeutic strategies against viral infections. -
Tyrosinase Inhibitor
2-Hydroxy-4-methoxybenzaldehyde is a potent inhibitor of the enzyme tyrosinase, which is crucial in melanin biosynthesis. This compound plays a significant role in research pertaining to pigmentation disorders and skin-related applications. Additionally, it can be utilized as a precursor for the synthesis of Urolithin M7, expanding its utility in biochemical studies. -
Aminopeptidase Inhibitor
Amastatin hydrochloride is a potent competitive inhibitor of aminopeptidases, exhibiting slow, tight binding kinetics. It demonstrates Ki values of 0.26 nM, 30 nM, and 52 nM against Aeromonas aminopeptidase, cytosolic leucine aminopeptidase, and microsomal aminopeptidase, respectively. This compound is valuable for research applications focusing on protein metabolism and post-translational modifications, as well as in studies exploring the role of aminopeptidases in various physiological and pathological processes. -
Caspase-3 Fluorogenic Substrate
Ac-DEVD-AFC is a fluorogenic substrate specifically designed for the detection of caspase-3 activity. Upon cleavage by caspase-3, it releases a fluorescent signal, enabling real-time monitoring of apoptosis. This reagent is widely used in cell biology research to evaluate programmed cell death and assess therapeutic effectiveness in various experimental settings. -
Caspase-1/4 Fluorometric Peptide Substrate
Ac-YVAD-AFC is a fluorometric peptide substrate specifically targeting caspase-1 and caspase-4. It exhibits an excitation wavelength of 400 nm and an emission wavelength of 505 nm, making it suitable for assessing caspase activity in various biological samples. This compound is commonly used in research applications focused on apoptosis, inflammation, and disease mechanisms involving these caspases. -
Caspase 8 Substrate
IETDC is a specific substrate for caspase 8, designed to monitor its activity through a bioluminescent assay. Upon cleavage by activated caspase 8, IETDC releases D-cysteine, which subsequently interacts with HCBT to generate firefly luciferin, producing a detectable bioluminescent signal. This reagent is particularly valuable for investigating acute inflammation and understanding the role of caspase 8 in apoptotic signaling pathways. -
Fluorogenic Caspase-8 Substrate
Ac-IETD-AMC is a fluorogenic substrate specifically designed for the detection and quantification of caspase-8 activity. This compound, which includes an acetyl (Ac) moiety, serves as an efficient tool for studying apoptosis and related pathways mediated by caspase-8 and granzyme B. Its application in research allows for precise measurement of caspase-8 activity in various biological contexts, facilitating insights into cell death mechanisms and potential therapeutic targets. -
DPP IV/CA Inhibitor
DPP IV/hCA II-IN-1 is a potent and selective inhibitor of dipeptidyl peptidase IV (DPP IV) and carbonic anhydrase (CA) enzymes. This compound exhibits a strong inhibitory effect on DPP IV with an IC50 value of 0.049 μM, while displaying varying Ki values for different carbonic anhydrase isoforms, including 0.0361 μM for CA II. Its dual-target inhibitory activity makes it a valuable tool for studying metabolic disorders and exploring therapeutic avenues in conditions involving DPP IV and CA dysregulation. -
DPP-4 Inhibitor
Gemigliptin tartrate is a selective and reversible inhibitor of dipeptidyl peptidase-4 (DPP-4), demonstrating an IC50 of 10.3 nM for human recombinant DPP-4. This compound exhibits significant anti-glycation properties, making it valuable for research into advanced glycation end products (AGEs) and their associated diabetic complications. Its specificity and efficacy position Gemigliptin tartrate as a useful tool in studies aimed at understanding and mitigating the effects of diabetes-related conditions. -
DPP-4 Inhibitor
Saxagliptin hydrochloride is a potent, selective, reversible inhibitor of dipeptidyl peptidase-4 (DPP-4), exhibiting an inhibition constant (Ki) of 0.6-1.3 nM. This compound is primarily employed in research focused on type 2 diabetes mellitus, as it enhances insulin secretion by increasing incretin levels, aiding in glucose regulation. Saxagliptin hydrochloride serves as a valuable tool for studying DPP-4's role in glucose homeostasis and potential therapeutic interventions in diabetes management. -
DPP-4 Inhibitor
Retagliptin is a selective, competitive inhibitor of dipeptidyl peptidase-4 (DPP-4) known for its oral bioavailability. It plays a crucial role in increasing incretin levels, which enhances insulin secretion and lowers glucagon levels in patients with type 2 diabetes mellitus (T2DM). This compound is valuable for research applications focused on the regulation of glucose homeostasis and the therapeutic potential in metabolic disorders. -
DPP-4 Inhibitor
Cofrogliptin is a potent oral dipeptidyl peptidase-4 (DPP-4) inhibitor. It exhibits long-acting antidiabetic efficacy, making it a promising candidate for the management of type 2 diabetes mellitus (T2DM). Cofrogliptin's mechanism of action enhances incretin levels, which supports insulin secretion and regulates glucose metabolism. This compound is valuable for research applications focused on diabetes treatment and metabolic disorders. -
DPP-4 Inhibitor
Sitagliptin fenilalanil is a potent dipeptidyl peptidase-4 (DPP-4) inhibitor that plays a crucial role in the regulation of glucose metabolism. By blocking the activity of DPP-4, it increases levels of incretin hormones, which enhance insulin secretion in response to meals and reduce glucagon levels. This compound is primarily utilized in diabetes research to explore therapeutic strategies for improving glycemic control and understanding the mechanisms of insulin regulation. -
DPP IV Inhibitor
Diprotin B is an inhibitor of dipeptidyl peptidase IV (DPP IV). By exhibiting competitive inhibition, Diprotin B mimics substrate behavior due to its tripeptide structure, particularly the presence of a proline residue at the penultimate position. This compound is utilized in research to study the modulation of glucose metabolism and to explore potential therapeutic applications in diabetes and related metabolic disorders. -
DPP-4 Inhibitor
Fotagliptin benzoate is a potent Dipeptidyl Peptidase IV (DPP-4) inhibitor with an IC50 value of 2.27 nM. It demonstrates a favorable safety profile in both rat and canine models. This compound is primarily utilized in research related to Type 2 diabetes mellitus, providing insights into glucose metabolism and potential therapeutic interventions. -
DPP1 Inhibitor
Propyl-GSK-2793660 hydrochloride is an irreversible and covalent inhibitor of Dipeptidyl Peptidase I (DPP1). This compound demonstrates significant inhibition of DPP1 activity, making it a valuable tool for investigating mechanisms related to bronchiectasis. Its application in research may facilitate the understanding of DPP1's role in various biological processes and potential therapeutic avenues. -
DPP-4 Inhibitor
Fotagliptin is a potent Dipeptidyl Peptidase IV (DPP-4) inhibitor with an IC50 of 2.27 nM. This compound is characterized by its favorable safety profile in rodent and canine models. Fotagliptin is primarily utilized in research related to Type 2 diabetes mellitus, contributing to investigations aimed at understanding glycemic control and insulin secretion mechanisms. -
DPP-4 Inhibitor
Sitagliptin fenilalanil hydrochloride is a potent inhibitor of dipeptidyl peptidase-4 (DPP-4), an enzyme involved in glucose metabolism. By blocking DPP-4 activity, this compound enhances the levels of incretin hormones, which promotes insulin secretion and lowers glucagon levels, thereby improving glycemic control. It is primarily used in research applications related to diabetes mellitus and metabolic disorders. -
DPP-IV Inhibitor
PK44 phosphate is a potent inhibitor of dipeptidyl peptidase IV (DPP-IV) with an IC50 value of 15.8 nM. It plays a critical role in regulating glucose metabolism and has potential applications in the treatment of type 2 diabetes. PK44 phosphate may also be used in pharmacological studies to explore the therapeutic effects of DPP-IV inhibition. -
DPP-4 Inhibitor
Teneligliptin-d8 is a deuterium-labeled analog of Teneligliptin, a competitive and durable inhibitor of dipeptidyl peptidase-4 (DPP-4). This compound is utilized in research to study the pharmacokinetics and metabolic pathways of Teneligliptin. Its potent inhibition of DPP-4 makes it significant for investigating therapeutic strategies for type 2 diabetes and related metabolic disorders. -
DPP II Substrate
Lys-Ala-pNA is a hydrolytic substrate specifically designed for dipeptidyl peptidase II (DPP II). Exhibiting a Michaelis constant (Km) of 0.42 mM, it serves as an effective tool for studying DPP II activity. This substrate is valuable in researching metabolic disorders and understanding DPP II's role in various physiological processes. -
DPP1 Inhibitor
AZD5248 is a selective inhibitor of dipeptidyl peptidase 1 (DPP1), a key enzyme involved in the regulation of peptide homeostasis. This compound demonstrates significant biological activity in the modulation of immune responses and is particularly relevant for research in chronic obstructive pulmonary disease (COPD) and other inflammatory lung disorders. Its ability to inhibit DPP1 makes it a valuable tool for investigating the therapeutic potential in respiratory diseases. -
DPP-4 Inhibitor
Evogliptin hydrochloride is a potent and selective inhibitor of Dipeptidyl Peptidase-4 (DPP-4), primarily utilized to enhance glycemic control in the management of type 2 diabetes. Its mechanism involves significant and sustained hypoglycemic effects while also reducing inflammatory and fibrotic signals in hepatocytes through the induction of autophagy. This compound is relevant for research exploring metabolic disorders, including type 2 diabetes, renal impairment, osteoporotic changes, and chronic liver inflammation. -
DPP4 Inhibitor
Dutogliptin tartrate is a potent and selective dipeptidyl peptidase-4 (DPP4) inhibitor. It demonstrates significant biological activity in the modulation of incretin hormones, thereby enhancing insulin secretion and lowering glucose levels. This compound is primarily utilized in research focused on the management and treatment of type 2 diabetes mellitus, contributing to the understanding of glucose metabolism and the role of DPP4 in diabetic pathophysiology. -
DPP-4 Inhibitor
Anagliptin hydrochloride is a potent and selective inhibitor of dipeptidyl peptidase 4 (DPP-4), exhibiting an IC50 of 3.8 nM. It demonstrates reduced selectivity for DPP-8 and DPP-9, with IC50 values of 68 nM and 60 nM, respectively. This compound is utilized in research focused on glycemic control and has applications in studying Type 2 diabetes and related metabolic disorders. -
DPP9 Inhibitor
DPP9-IN-2 is a selective, potent inhibitor of Dipeptidyl Peptidase 9 (DPP9), exhibiting an IC50 of 12.9 nM. It demonstrates a selectivity index of 59 over DPP8 and shows minimal inhibitory effects on related peptidases, including DPP2, DPP4, FAP, and PREP. DPP9-IN-2 has been shown to induce pyroptosis in cancer cells and exhibits weak synergistic anti-HIV-1 activity when combined with non-nucleoside reverse transcriptase inhibitors. This compound is suitable for research related to cancer and infectious diseases. -
DPP-IV Inhibitor
NVP-DPP728 dihydrochloride is a selective and potent inhibitor of dipeptidyl peptidase IV (DPP-IV), with a Ki value of 11 nM. This compound plays a critical role in the regulation of glucose metabolism and is utilized in research related to diabetes mellitus. NVP-DPP728 dihydrochloride offers valuable insights into the therapeutic potential of DPP-IV inhibition in glycemic control and metabolic diseases. -
DPP-4 Inhibitor
ZY15557 is a novel competitive DPP-4 inhibitor with a Ki of 5.53 nM, demonstrating significant potency in inhibiting plasma DPP-4 activity. This orally active compound is useful in the investigation of type 2 diabetes and its potential therapeutic strategies. Research applications include studying glucose metabolism and insulin secretion modulation associated with DPP-4 inhibition. -
DPP-IV Inhibitor
RBx-0597 is a selective inhibitor of Dipeptidyl Peptidase IV (DPP-IV), exhibiting IC50 values of 32 nM, 31 nM, and 39 nM for human, mouse, and rat plasma DPP-IV, respectively. This compound shows promise in the investigation of type 2 diabetes by modulating glucose metabolism and incretin levels, making it a valuable tool for diabetes research and related metabolic studies. -
DPP-IV Inhibitor
O-Benzoylhydroxylamine is a selective inhibitor of Dipeptidyl Peptidase IV (DPP-IV), a key enzyme involved in glucose metabolism. By inhibiting DPP-IV, this compound exhibits significant anti-diabetic effects, making it valuable for research into diabetes management and related metabolic disorders. Its mechanisms and targets are critical for understanding the pathways influenced by DPP-IV inhibition. -
DPP4 Inhibitor
ASP4000 hydrochloride is a potent, selective inhibitor of dipeptidyl peptidase IV (DPP4), exhibiting an IC50 value of 2.25 nM against human recombinant DPP4. This compound demonstrates significant antihyperglycemic effects, making it valuable in studies related to type 2 diabetes research. Its oral bioavailability and competitive inhibition profile allow for potential applications in understanding DPP4's role in glucose metabolism and diabetes management. -
DPP4 Inhibitor
ZINC000003015356 is a DPP4 inhibitor that selectively blocks the activity of the dipeptidyl peptidase-4 enzyme. This inhibition enhances the availability of incretin hormones, which are crucial for glucose metabolism. ZINC000003015356 is primarily used in research related to diabetes and metabolic disorders, contributing to studies focused on glycemic control and potential therapeutic strategies. -
Serine Aminopeptidase
Dipeptidyl Peptidase IV, Porcine Kidney is a serine aminopeptidase that plays a vital role in glucose metabolism. This enzyme specifically hydrolyzes gastric inhibitory peptide (GIP) and glucagon-like peptide-1 (GLP-1), which are key incretins involved in insulin release regulation. Its biological activity makes it a valuable tool for research in diabetes, metabolism, and related endocrine functions. -
DPP-IV Inhibitor
H-Pro-Pro-Gln-OH is an oligopeptide that acts as a potent inhibitor of dipeptidyl peptidase-IV (DPP-IV). This compound exhibits significant biological activity in modulating insulin secretion and glucose metabolism, making it a valuable tool for diabetes research. Its effective inhibition of DPP-IV may contribute to therapeutic strategies in managing type 2 diabetes and related metabolic disorders. -
DPP-8/9 Inhibitor
DPP-8/9 probe-1 is a selective inhibitor targeting Dipeptidyl Peptidase DPP8/9, designed for use in fluorescence microscopy. This fluorescent probe features a nitrobenzoxadiazole (NBD) tag, demonstrating high affinity for DPP8/9 with an IC50 of 15 nM, while showing minimal activity against related S9 family members (IC50 of 210 nM). DPP-8/9 probe-1 enables visualization of active DPP8/9 in vitro, making it a valuable tool for studying the biological functions and pathways associated with this enzyme in research settings.
